Skip to content

A prospective, multi-center study of Apatinib in the treatment of advanced cancer

A prospective, multi-center study of Apatinib in the treatment of advanced cancer

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-15007034
Enrollment
Unknown
Registered
2015-09-09
Start date
2015-09-02
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

none:none

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age: over 18 years old; 2. Pathologically diagnosed with advanced cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring >=10mm on spiral CT scan, tisfying the criteria in RECIST 1.1); 3. Failure of prior therapy (during or after treatment) in patients who have received at least two prior chemotherapy regimens; 4. The patients have indications for treatment no absolute contraindications for chemotherapy; 5. Patient has to voluntarily join the study sign the Informed Consent Form for the study.

Exclusion criteria

Exclusion criteria: 1. patients who are allergic to lapatinib or any of the ingredients in lapatinib tablets; 2. Pregnant or lactating women; 3. patients with contraindication; 4. patients who physicians suggest not be included.

Design outcomes

Primary

MeasureTime frame
Progression-free survival (PFS);

Countries

China

Contacts

Public ContactZhuang Zhixiang
sdfeyzzx@sina.com+86 13951106391

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 24, 2026